srt2104
Small moleculeexperimental
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00933530)
Timeline
Indications
Mechanism of action
- NAD-dependent deacetylase sirtuin 1ACTIVATOR
SIRT1 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- srt2104
- srt2104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01702493 | Phase 1 | Oct 30, 2012 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT01453491 | Phase 1 | Feb 13, 2012 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT01039909 | Phase 1 | Jan 1, 2011 | GlaxoSmithKline |
| NCT01154101 | Phase 2 | Jun 1, 2010 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT01031108 | Phase 1 | May 28, 2010 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT01018017 | Phase 2 | Mar 3, 2010 | GlaxoSmithKline |
| NCT01014117 | Phase 1 | Dec 9, 2009 | GlaxoSmithKline |
| NCT00964340 | Phase 1 | Oct 1, 2009 | GlaxoSmithKline |
| NCT00937326 | Phase 2 | Aug 1, 2009 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT00920660 | Phase 1 | Apr 1, 2009 | GlaxoSmithKline |
| NCT00933062 | Phase 1 | Mar 1, 2009 | GlaxoSmithKline |
| NCT00938275 | Phase 1 | Jan 1, 2009 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT00937872 | Phase 1 | Nov 22, 2008 | GlaxoSmithKline, Sirtris Pharmaceuticals |
| NCT00933530 | Phase 1 | May 1, 2008 | GlaxoSmithKline, Sirtris Pharmaceuticals |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 14 | 6 | 2 | 2008 |
| Sirtris Pharmaceuticals | For profit | 8 | 8 | 2 | 2008 |
2 organizations
Page 1 / 1